Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke

Trial Profile

Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ACTION2
  • Sponsors Biogen
  • Most Recent Events

    • 11 Apr 2017 Planned End Date changed from 1 Mar 2018 to 28 Feb 2018.
    • 11 Apr 2017 Planned primary completion date changed from 1 Mar 2018 to 28 Feb 2018.
    • 26 Jan 2017 Planned number of patients changed from 240 to 270.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top